glucagon

Short version of the title, which is already short: ERP reta — PeptideMeter came back 98.9% against a claimed 98.0%. Longer version underneath. Figures up front so…

someone explain survodutide to me like I have not read a paper in years. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers…

Six-word version is the title — anyone else notice survodutide kicking in around week 93 — and the rest is context. Read the phase 2 hepatic paper properly and the…

unpopular opinion: most of what gets said here about triple agonist is guesswork, which sounds obvious until you try to state the evidence for it. Kept a log…

Posting this as a discussion rather than a claim: this is not approved anywhere and half this community forgets that. What the glucagon arm is doing, as best anyone can…

retatrutide — what am I missing here — that is what I am asking, and I have already read the wiki twice. Read the phase 2 paper twice before ordering anything.…

4 months in and MASH is still the thing I get wrong. Numbers below. Ask me the boring questions, they are the useful ones. Numbers, in the order they matter: 4 months.…

WWB survo — Medutest came back 99.2% against a claimed 98.5%. One vial, one service, one member paying, which is the only kind of result this board should treat as…

Thinking out loud about this: my A1c moved and I cannot work out whether TRIUMPH is why. Nothing containing this compound is approved anywhere. Research-use-only…

why does nobody talk about dual agonist, and I want the answer with the reasoning attached rather than just the conclusion. Assumed the weight numbers were the point…

hepatic fat: the version I wish someone had shown me in week 1. Full detail below, and I have tried to keep the editorialising out of it. Bought small because the…

small win: dose escalation stopped being a problem at week 19. This is a description of what happened to me and not a plan for anybody else. What the glucagon arm is…

The phase 2 MASH results ( NEJM , 2024) are, to me, the most underdiscussed thing in this whole space. Biopsy-confirmed endpoints. Not an ALT screenshot, not imaging,…

the dose escalation question that gets asked weekly, answered properly. Making the case below, and I expect to lose some of it in the comments. Stopped at a low step…

tried triple agonist for 19 weeks. here is what happened, and I am aware this is a minority view on this board. The numbers the title promised, since a headline without…

Thinking out loud about this: three years of MASH threads, summarised so you do not have to read them. Spent an evening on the histology scoring system and understood…

The title is the whole question — is anyone tracking heart rate properly on reta or are we all guessing — but here is why I am asking. Independent purity testing on…

retatrutide: what the trials say vs what this community says. I have gone back and forth on this for months. Where the evidence actually stands, since every thread here…

Short public-service post: TRIUMPH is not what most of this community thinks it is. Went up slowly, deliberately, because everything on this board says the escalation…

MASH — my 24-week log, condensed into one table, which sounds obvious until you try to state the evidence for it. It is a dual agonist at the GLP-1 and glucagon…

Check-in as promised in the title: is it normal to get early fullness at week 64. Nothing containing this compound is approved anywhere. Research-use-only material is…

split one vial across VendorInvestigate and PeptideMeter — 98.6% and 93.7%. I will put the method line and the batch identifier up front because that is what makes this…

the retatrutide rule is doing its job and people should stop complaining. Short post, long comment section, probably. Independent purity testing on this compound is…

Trying to get a straight answer on this: why does nobody talk about survodutide. Went slowly because everything published describes a deliberate escalation. That is the…

dual agonist is the most under-discussed thing on this board. I have gone back and forth on this for months. Phase 2 in a biopsy-confirmed population is a demanding…